Article

Bausch & Lomb shareholders approve merger with Warburg Pincus affiliates

Rochester, NY-Bausch & Lomb shareholders have approved the proposed merger of the company with affiliates of Warburg Pincus LLC, according to the company.

Rochester, NY-Bausch & Lomb shareholders have approved the proposed merger of the company with affiliates of Warburg Pincus LLC, according to the company.

“We look forward to promptly completing the transaction,” said Ronald L. Zarrella, chairman and chief executive officer of Bausch & Lomb.

The deal is expected to close early in the fourth quarter. Each outstanding share of Bausch & Lomb common and Class B stock will be canceled and converted into the right to receive $65 in cash, without interest and minus any applicable withholding taxes.

Affiliates of Warburg Pincus are not required to consummate the merger until after expiration of a “marketing period” of 20 business days after the shareholder vote, which was held Sept. 21.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.